ArticleCureus2025
Effect of Methotrexate on Semen Parameters in Psoriatic Male Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 60 million people worldwide. Methotrexate (MTX), a folate antagonist, is frequently prescribed as a systemic treatment for moderate-to-severe psoriasis due to its immunosuppressive efficacy and cost-effectiveness. Despite its long-standing use, concerns persist regarding its potential impact on male fertility, particularly on semen parameters. Objective To evaluate the impact of methotrexate treatment on semen parameters in male patients with psoriasis. Methods This prospective pre-post cohort study included 31 male psoriasis patients aged 18-50, treated with MTX for at least three months. Patients with systemic illnesses (e.g., diabetes, cardiovascular disease), endocrine disorders (e.g., thyroid dysfunction), autoimmune diseases (e.g., lupus, rheumatoid arthritis), genetic syndromes, or recent hormonal therapy (e.g., testosterone, anabolic steroids, or gonadotropins) within three months were excluded. Semen analyses were conducted immediately before initiating MTX therapy and again after completing three continuous months of treatment, without discontinuation, Data were analyzed using a paired t-test to compare pre- and post-treatment continuous variables, including semen volume, pH, sperm concentration, motility, morphology, and pus cell count (WBCs) using WHO 2010 criteria. Categorical data were summarized using frequencies and percentages. A p-value < 0.05 was considered statistically significant. Results The mean age of the study participants was 34.84 ± 9.78 years. No statistically significant differences (all p > 0.05) were observed pre- and post-treatment in semen volume (3.01 ± 1.61 vs. 3.12 ± 0.88 mL), pH (7.57 ± 0.11 vs. 7.56 ± 0.096), total sperm motility (46.61 ± 20.97% vs. 46.01 ± 21.14%), sperm morphology (19.26 ± 9.99% vs. 19.49 ± 11.90%), sperm concentration (50.21 ± 21.75 vs. 61.20 ± 29.56 million/mL), or pus cell count in semen (2.94 ± 2.29 vs. 2.80 ± 2.28). Conclusion Methotrexate treatment over three months did not lead to statistically significant changes in semen parameters among psoriatic male patients, indicating no observed short-term adverse effects on male reproductive indicators. Given the small sample size and absence of a control group, these findings should be considered preliminary and warrant further validation in larger, controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.